BioCircuit Technologies®, a medical device company focused on peripheral nerve repair and neuromodulation, announces the close of a $9 million round of financing. Mike Masters of Masters Capital, the GRA Venture Fund and Alsora Capital continued their support, alongside existing shareholders. “We are very grateful to our investors for the support they have shown and continue to show for BioCircuit,” says Michelle Jarrard, CEO of BioCircuit. “The company has achieved a number of important milestones during the last year, including FDA 510(k) clearance for our first device, and we are now in a position to scale with confidence.”